PT3145553T - Arn de interferência pequeno (arnsi) para a terapêutica da osteopetrose autossómica dominante de tipo 2 (ado2) causada por mutação génica de clcn7 (ado2 dependente de clcn7) - Google Patents

Arn de interferência pequeno (arnsi) para a terapêutica da osteopetrose autossómica dominante de tipo 2 (ado2) causada por mutação génica de clcn7 (ado2 dependente de clcn7)

Info

Publication number
PT3145553T
PT3145553T PT157323874T PT15732387T PT3145553T PT 3145553 T PT3145553 T PT 3145553T PT 157323874 T PT157323874 T PT 157323874T PT 15732387 T PT15732387 T PT 15732387T PT 3145553 T PT3145553 T PT 3145553T
Authority
PT
Portugal
Prior art keywords
ado2
clcn7
sirna
therapy
dependent
Prior art date
Application number
PT157323874T
Other languages
English (en)
Inventor
Maria Teti Anna
Rucci Nadia
Capulli Mattia
Maurizi Antonio
Original Assignee
Univ Degli Studi Dellaquila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Dellaquila filed Critical Univ Degli Studi Dellaquila
Publication of PT3145553T publication Critical patent/PT3145553T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses
PT157323874T 2014-05-23 2015-05-21 Arn de interferência pequeno (arnsi) para a terapêutica da osteopetrose autossómica dominante de tipo 2 (ado2) causada por mutação génica de clcn7 (ado2 dependente de clcn7) PT3145553T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM20140272 2014-05-23

Publications (1)

Publication Number Publication Date
PT3145553T true PT3145553T (pt) 2019-10-30

Family

ID=51220775

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157323874T PT3145553T (pt) 2014-05-23 2015-05-21 Arn de interferência pequeno (arnsi) para a terapêutica da osteopetrose autossómica dominante de tipo 2 (ado2) causada por mutação génica de clcn7 (ado2 dependente de clcn7)

Country Status (11)

Country Link
US (1) US10450571B2 (pt)
EP (1) EP3145553B1 (pt)
JP (1) JP6795492B2 (pt)
AU (1) AU2015262889B2 (pt)
CA (1) CA2949345C (pt)
DK (1) DK3145553T3 (pt)
ES (1) ES2753355T3 (pt)
HU (1) HUE046546T2 (pt)
PL (1) PL3145553T3 (pt)
PT (1) PT3145553T (pt)
WO (1) WO2015177743A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111235152A (zh) * 2020-03-31 2020-06-05 深圳市人民医院 特异性靶向CLCN7的sgRNA及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079414A2 (en) * 2001-03-29 2002-10-10 Deltagen, Inc. Transgenic mice containing clcn7 chloride channel gene disruptions
WO2003062821A1 (en) * 2002-01-23 2003-07-31 Bristol-Myers Squibb Company Modulators of the clc-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA

Also Published As

Publication number Publication date
PL3145553T3 (pl) 2020-03-31
WO2015177743A1 (en) 2015-11-26
CA2949345A1 (en) 2015-11-26
EP3145553B1 (en) 2019-07-31
CA2949345C (en) 2022-06-14
AU2015262889B2 (en) 2020-04-23
US20170101644A1 (en) 2017-04-13
US10450571B2 (en) 2019-10-22
AU2015262889A1 (en) 2016-12-01
DK3145553T3 (da) 2019-10-28
JP6795492B2 (ja) 2020-12-02
ES2753355T3 (es) 2020-04-08
JP2017521094A (ja) 2017-08-03
AU2015262889A8 (en) 2017-02-02
EP3145553A1 (en) 2017-03-29
HUE046546T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
HK1251615A1 (zh) 常染色體顯性疾病的基因治療
IL255288A0 (en) Regulation of nuclease-mediated gene expression
LT3337902T (lt) 3` utr sekos, skirtos rnr stabilizavimui
ZA201604874B (en) Rna-guided gene drives
EP3224353A4 (en) Targeted elimination of bacterial genes
EP3159409A4 (en) Antisense nucleic acid
IL284577A (en) Garden healing
EP3118311A4 (en) Antisense nucleic acid
EP3222728A4 (en) Method for regulating gene expression using cas9 protein expressed from two vectors
HUE052552T2 (hu) Javított nukleinsav-konstrukciók eukarióta génexpresszióhoz
EP3351633A4 (en) Antisense Nucleic Acid
HK1258518A1 (zh) 用於眼病的基因療法
EP3158067A4 (en) Compositions and methods for regulating gene expression via rna interference
EP3323893A4 (en) BETA2GPI GENE EXPRESSION-INHIBITING NUCLEIC ACID COMPLEX
IL282752A (en) Methods for altering gene expression for genetic disorders
EP3290518A4 (en) Novel gene targeting method
IL271595A (en) Compounds for reducing deleterious activity of genes comprising an expanded nucleotide repeat
EP3286310A4 (en) REACTIVATION OF X-CHROMOSOME GENES
IL267057A (en) Gene therapy for the treatment of mucoid polysaccharomyces type i
EP3099304A4 (en) Novel therapeutics for the treatment of glaucoma
HK1253299A1 (zh) 一種通過基因治療治療眼疾病的改進方法
IL254304A0 (en) Nucleoside agents to reduce negative effects of genes involving elongated nucleotide repeats
EP3133923A4 (en) Aav-based gene therapy for multiple sclerosis
GB201707212D0 (en) Gene therapy for ciliopathies
PL3145553T3 (pl) Mały interferujący RNA (siRNA) do leczenia autosomalnej, dominującej osteopetrozy spowodowanej mutacją genu CLCN7 (ADO2 zależnej od CLCN7)